<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667104</url>
  </required_header>
  <id_info>
    <org_study_id>CR108928</org_study_id>
    <secondary_id>2020-003956-34</secondary_id>
    <secondary_id>73763989PAHPB2006</secondary_id>
    <nct_id>NCT04667104</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</brief_title>
  <acronym>PENGUIN</acronym>
  <official_title>A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen&#xD;
      (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 +&#xD;
      nucleos[t]ide analog [NA] and pegylated interferon alpha-2a [PegIFN-alpha2a].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an intervention specific appendix to the Hepatitis B wings platform trial&#xD;
      (PLATFORMPAHPB2001).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">May 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Reduction of at Least 2 log10 IU/mL in Hepatitis B Surface Antigen (HBsAg) Levels</measure>
    <time_frame>From Baseline up to Week 24 (end of study intervention)</time_frame>
    <description>Percentage of participants with a reduction of at least 2 log10 international units per milliliter (IU/mL) in HBsAg levels from baseline to Week 24 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormalities in Vital Signs and Clinically Significant Laboratory Findings as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Number of participants with abnormalities in vital signs and clinically significant laboratory findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in 12-Lead Electrocardiogram (ECGs)</measure>
    <time_frame>Up to Week 28</time_frame>
    <description>Percentage of participants with abnormalities (heart rate, PR, QRS and QT corrected [QTc]) in 12- lead ECGs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormalities in Ophthalmic and Physical Examination as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Number of participants with abnormalities in ophthalmic and physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Protocol-defined Nucleos(t)ide Analog (NA) Treatment Completion Criteria at End of Study Intervention (EOSI)</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOSI will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hepatitis B e Antigen (HBeAg), HBsAg, and Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) and ALT Levels</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with HBeAg, HBsAg, and HBV DNA levels and alanine aminotransferase (ALT) levels below/above different cut-offs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg and HBeAg Seroconversion</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with HBsAg and HBeAg seroconversion (Unit: International units per milliliter) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in HBsAg, HBeAg and HBV DNA Levels</measure>
    <time_frame>Baseline, Up to Week 72</time_frame>
    <description>Change from baseline over time in HBsAg, HBeAg and HBV DNA levels (Unit: International units per milliliter) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve HBsAg, HBeAg and HBV DNA Levels Seroclearance/Seroconversion</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Time to achieve HBsAg, HBeAg and HBV DNA levels seroclearance/seroconversion (Unit: International units per milliliter) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with virologic breakthrough will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA &lt; LLOQ</measure>
    <time_frame>At Week 48</time_frame>
    <description>Percentage of participants with HBV DNA &lt; LLOQ will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic and/or Biochemical Flares</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with virologic and/or biochemical flares will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring NA Re-treatment</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants requiring NA re-treatment based on failure in NA treatment completion criteria will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of of JNJ-3989</measure>
    <time_frame>Predose and 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hour, 8 hours,10 hours, and 24 hours post dose (on day 29 and 141)</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of JNJ-3989.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of JNJ-6379</measure>
    <time_frame>Predose and 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hour, 8 hours,10 hours, and 24 hours post dose (on day 29 and 141)</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of JNJ-6379.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Nucleos(t)ide Analog</measure>
    <time_frame>Predose and 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hour, 8 hours,10 hours, and 24 hours post dose (on day 29 and 141)</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of nucleos(t)ide analog.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of PegIFN-alpha2a</measure>
    <time_frame>Predose and 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hour, 8 hours,10 hours, and 24 hours post dose (on day 29 and 141)</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of PegIFN-alpha2.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination treatment with JNJ-73763989 + 56136379 + nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + 56136379 + NA plus PegIFN-Î±2a for 12 weeks during Treatment Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-73763989</intervention_name>
    <description>JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.</description>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
    <other_name>JNJ-3989</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>JNJ-56136379 tablets will be administered orally once daily.</description>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
    <other_name>JNJ-6379</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Tenofovir disoproxil film-coated tablet will be administered orally once daily.</description>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide (TAF)</intervention_name>
    <description>TAF film-coated tablet will be administered orally once daily.</description>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir (ETV) monohydrate</intervention_name>
    <description>ETV monohydrate film-coated tablet will be administered orally once daily.</description>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN-alpha2a</intervention_name>
    <description>PegIFN-alpha2a injection will be administered subcutaneously once weekly.</description>
    <arm_group_label>Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) infection, hepatitis B e Antigen (HBeAg) positive or&#xD;
             negative with suppressed viral replication under nucleos(t)ide analogue treatment for&#xD;
             at least 6 months prior to screening&#xD;
&#xD;
          -  Medically stable based on physical examination, medical history, vital signs, and&#xD;
             12-lead electrocardiogram (ECG) performed at screening&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m^2),&#xD;
             extremes included&#xD;
&#xD;
          -  Must have serum HBsAg greater than (&gt;) 100 international units per milliliter (IU/mL)&#xD;
             at screening, as assessed by quantitative HBsAg assay&#xD;
&#xD;
          -  Must have a fibroscan stiffness measurement less than or equal to (&lt;=) 9.0 Kilopascal&#xD;
             (kPa) at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of hepatitis A, C, D or E virus infection or human immunodeficiency, virus&#xD;
             type 1 (HIV) or HIV-2 infection at screening&#xD;
&#xD;
          -  History or evidence of clinical signs or symptoms of hepatic decompensation, including&#xD;
             but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal&#xD;
             varices&#xD;
&#xD;
          -  Evidence of liver disease of non-HBV etiology&#xD;
&#xD;
          -  Participants with a history of malignancy within 5 years before screening&#xD;
&#xD;
          -  Contraindications to the use of pegylated interferon alpha-2a&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Medical Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middlemore Clinical Trials</name>
      <address>
        <city>Papatoetoe</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska</name>
      <address>
        <city>Gdansk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zakazny w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny SA</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108928</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

